Posted by Michael Wonder on 23 Sep 2019
Annexon Biosciences announces FDA fast track designation for novel C1q inhibitor ANX005 for the treatment of Guillain-Barré syndrome
23 September 2019 - Annexon plans to advance the clinical development of ANX005 for the treatment of GBS.
Annexon Biosciences announced today that the U.S. FDA has granted fast track designation for ANX005 for the treatment of Guillain-Barré Syndrome (GBS), a rare, acute, antibody-mediated autoimmune disease impacting the peripheral nervous system for which there are currently no approved therapies in the United States.
The FDA had previously granted orphan drug designation for ANX005 for the treatment of GBS.
